Gillian McGovern, Associate Editor

After decades without improvements, an expert with Baptist Health described the small cell lung cancer (SCLC) space as “exciting” following multiple innovations in the past few years.

Vutrisiran becomes the first and only therapeutic FDA-approved to treat cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults.

Approximately 74% of patients with chronic rhinosinusitis with nasal polyps receiving depemokimab across 2 trials did not need additional intervention.

Patients with chronic hepatitis B (CHB) who received the Hecolin hepatitis E virus (HEV) 3-dose regimen had a somewhat low incidence of local and systemic adverse events.

The treatment is indicated for patients aged 6 and older with hypertension, the reduction of stroke in hypertension and left ventricular hypertrophy, and diabetic nephropathy in certain patients with type 2 diabetes.

The new indication would include adults with heart failure with a left ventricular ejection fraction (LVEF) of 40% or higher, such as mildly reduced or preserved LVEF.

Data from conference abstracts and presentations indicate that both preexposure prophylaxis methods continue to demonstrate efficacy.

DC646 had a strong safety profile, targeted intestinal FXR, and disrupted FXR-co-activator interactions in metabolic dysfunction-associated steatohepatitis (MASH).

The authors note that further research is needed to clarify cost-effectiveness, long-term adherence, and psychosocial impacts of oral immunotherapy.

Some of these approaches for chronic kidney disease (CKD) include cystatin C, SGLT2 inhibitors, point-of-care testing in remote areas, and acid-lowering medications.

Untargeted lipidomics identified a glycerophospholipid and sphingolipid signature that differentiated severe alcohol-related hepatitis (sAH) from decompensated cirrhosis (DC).

Although the 16-week end point was not met, tezepelumab demonstrated meaningful effects in patients with chronic spontaneous urticaria (CSU) after 32 weeks.

Although improvements were observed in blood pressure (BP) medication adherence, there were no improvements in stain or glucose-lowering medication use.

Currently, EN001 is undergoing evaluation in a phase 1b trial.

The cancers linked with per- and polyfluoroalkyl substance (PFAS) exposure included nonastrocytoma gliomas, acute myeloid leukemia, and Wilms tumors.

The treatment is currently undergoing evaluation in an investigational preclinical program and is projected to be in human trials in 2026.

The treatment's expanded indication for chronic kidney disease (CKD) is expected to be available by April 2025.

The approval is based on results from 2 phase 3 clinical trials that showed revakinagene taroretcel’s efficacy in macular telangiectasia type 2 (MacTel).

The move is expected to expand clozapine access for patients with schizophrenia.

Pharmacists also educate, advocate, and ensure patients with heart failure with reduced ejection fraction (HFrEF) and anemia are receiving the appropriate regimens.

Tezepelumab demonstrated efficacy compared with placebo when treating patients with chronic rhinosinusitis with nasal polyps.

The designation was granted after positive results from the phase 1 STOMP-I clinical trial (NCT01915927).

The action follows pooled data from 2 studies that enrolled patients with hemophagocytic lymphohistiocytosis (HLH)/macrophage activation syndrome (MAS) in Still disease.

Additional risk factors included older age and advanced chronic kidney disease (CKD) stage.

In a clinical trial, tenecteplase was shown to be a comparable alternative to alteplase.

The feature is expected to be available to US users in late March 2025.

The updated indication now includes pediatric patients aged 5 through 11 years.

Patients with metabolic dysfunction-associated steatohepatitis (MASH) receiving 300 mg of vitamin E daily presented improved steatosis, lobular inflammation, and fibrosis stages.

Health care professionals and patients must recognize that rapid administration of adrenaline is the only first-line treatment for anaphylaxis.

If approved, gepotidacin (GSK) will be a new oral agent added to the treatment paradigm for urinary tract infections (UTIs).